(S)-2-(4-(3,5-difluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)propan-2-ol | 1319590-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (S)-2-(4-(3,5-difluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)propan-2-ol
• 英文别名: 2-[(2S)-4-[3,5-difluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl]piperazin-2-yl]propan-2-ol
• CAS: 1319590-89-0
• 化学式: C₁₈H₂₀F₂N₆O
• 分子量: 374.393
• InChiKey: YWYFIEZNSRKWIT-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  90
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,3,5-三氟吡啶 在 正丁基锂 、 四丁基氟化铵 、 一水合肼 、 二异丙胺 、 calcium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 为溶剂， 反应 3.75h， 生成 (S)-2-(4-(3,5-difluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)propan-2-ol
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINE KINASE INHIBITORS
  [FR] INHIBITEURS DE LA PYRAZOLOPYRIDINE KINASE

  摘要：

  本发明涉及用作蛋白激酶抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病、病况或障碍的方法。本发明还提供了制备本发明中化合物的方法。

  公开号：

  WO2011094283A1

文献信息

• PYRAZOLOPYRIDINE KINASE INHIBITORS
  申请人：Jimenez Juan-Miguel

  公开号：US20130053395A1

  公开（公告）日：2013-02-28

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及用作蛋白激酶抑制剂的化合物。本发明还提供了包含该化合物的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病、病况或疾患的方法。本发明还提供了制备本发明化合物的方法。
• STEM CELL MODULATION II
  申请人：EpiAxis Therapeutics Pty Ltd

  公开号：EP3046560B1

  公开（公告）日：2021-01-06
• Stem Cell Modulation II
  申请人：UNIVERSITY OF CANBERRA

  公开号：US20160354367A1

  公开（公告）日：2016-12-08

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
• Compositions for Modulating Cancer Stem Cells and Uses Therefor
  申请人：University of Canberra

  公开号：US20170266140A1

  公开（公告）日：2017-09-21

  Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.
• IMMUNOGENIC COMPOSITIONS AND USES THEREFOR
  申请人：Epiaxis Therapeutics Pty Ltd

  公开号：US20200282010A1

  公开（公告）日：2020-09-10

  The present invention discloses the use of protein kinase C (PKC-θ) inhibitors for enhancing the immune effector function of functionally repressed T-cells that have undergone epithelial to mesenchymal transition (EMT). In specific embodiments, PKC-θ inhibitors are disclosed for use in enhancing susceptibility of exhausted T-cells to reinvigoration by PD-1 binding antagonists. The compositions of the present invention find utility in treating a range of disorders including T-cell dysfunctional disorders such as pathogenic infections and hyperproliferative disorders.